Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers

Journal of Chemotherapy

Volumn 20, Issue 1, 2008, Pages 28-32

  Sader, Helio S ^a,b   Watters, A A ^a   Fritsche, T R ^a   Jones, R N ^a,c  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bacteremia; Daptomycin; Endocarditis; Levofloxacin; Linezolid; Oxacillin; Vancomycin

Indexed keywords

COTRIMOXAZOLE; DALFOPRISTIN; DAPTOMYCIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; QUINUPRISTIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; BROTH DILUTION; CATHETER INFECTION; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; DRUG POTENCY; FOOD AND DRUG ADMINISTRATION; HUMAN; INTRAVENOUS CATHETER; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CATHETERS, INDWELLING; DAPTOMYCIN; EUROPE; HOSPITALIZATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE EAST; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 41149095636     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1994; 271 (20): 1598-601.
2. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000; 118 (1): 146-55.
3. Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: A review 4 years after first approval. Pharmacology. 2007; 81 (2): 79-91.
4. Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: A SENTRY Program Report (2003-2004). Int J Antimicrob Agents. 2007; 30 (2): 143-9.
5. Sader HS, Fritsche TR, Jones RN. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother. 2006; 50 (7): 2330-6.
6. Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003; 47 (5): 1714-8.
7. Cubicin Product Information. European Medicines Agency. http://www.emea.eu.int/humandocs/Humans/EPAR/cubicin/cubicin.htm. Accessed July 1, 2007. 2006.
8. Package Insert. Cubicin (daptomycin for injection). Lexington MA. (Cubist Pharmaceuticals, Inc). Available at http://www.cubicin.com/2006_full_pi.pdf. Accessed on July, 1, 2007. 2006.
9. Fowler VG, Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006; 355 (7): 653-65.
10. Levine DP, Lamp KC. Daptomycin in the treatment of patients with infective endocarditis: Experience from a registry. Am J Med. 2007; 120 (10 Suppl 1): S28-33.
11. Clinical and Laboratory Standards Institute (CLSI). M7-A7, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - seventh edition. Wayne, PA:CLSI, 2006.
12. Clinical and Laboratory Standards Institute. M100-S17, Performance standards for antimicrobial susceptibility testing, 17th informational supplement. Wayne, PA: CLSI, 2007.
13. EUCAST. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. EUCAST Technical Note on daptomycin. Clin Microbiol Infect. 2006; 12 (6): 599-601.
14. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antibacterial agents; approved guideline. Approved Standard M26-A. Wayne, PA: NCCLS, 1999.
15. Moody J, Knapp C. Tests to assess bactericidal activity. In: Insenberg HD, editor. Clinical Microbiology Procedures Handbook. Washington, DC: ASM Press; 2004. p. 5.10.1.1-5..3.6.
16. Asseray N, Jacqueline C, Le Mabecque V, et al. Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy. Antimicrob Agents Chemother. 2005; 49 (2): 857-9.
17. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis. 2004; 38 (6): 864-70.
18. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004; 48 (12): 4665-72.
19. Drake TA, Sande MA. Studies of the chemotherapy of endocarditis: Correlation of in vitro, animal model and clinical studies. Rev Infect Dis. 1985; 5 (Suppl 2): S345-53.
20. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother. 1990; 34 (6): 1227-31.
21. Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: Results of the Daptomycin Surveillance Programme (2002-2004). Clin Microbiol Infect. 2006; 12 (9): 844-52.